Ricky Goldwasser
Stock Analyst at Morgan Stanley
(3.32)
# 1,041
Out of 5,138 analysts
230
Total ratings
62.89%
Success rate
9.48%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DOCS Doximity | Upgrades: Overweight | $62 → $65 | $41.05 | +58.34% | 11 | Dec 15, 2025 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $170 → $185 | $223.47 | -17.21% | 23 | Nov 11, 2025 | |
| CNC Centene | Maintains: Equal-Weight | $28 → $38 | $47.27 | -19.61% | 14 | Oct 14, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $325 → $395 | $338.96 | +16.53% | 20 | Sep 12, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $268.89 | +13.80% | 17 | Jul 25, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $7.44 | +34.41% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $2.68 | +105.22% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $17.42 | -56.95% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $22.50 | -46.67% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $190.26 | -23.79% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $193.74 | +88.40% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $844.13 | -50.24% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $4.76 | +2,421.01% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $283.95 | +118.35% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $381.93 | +30.91% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $81.36 | +52.41% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $277.94 | +14.41% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $213.46 | -67.21% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $241.28 | -19.18% | 6 | Oct 21, 2020 |
Doximity
Dec 15, 2025
Upgrades: Overweight
Price Target: $62 → $65
Current: $41.05
Upside: +58.34%
Charles River Laboratories International
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $170 → $185
Current: $223.47
Upside: -17.21%
Centene
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $28 → $38
Current: $47.27
Upside: -19.61%
UnitedHealth Group
Sep 12, 2025
Maintains: Overweight
Price Target: $325 → $395
Current: $338.96
Upside: +16.53%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $268.89
Upside: +13.80%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $7.44
Upside: +34.41%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $2.68
Upside: +105.22%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $17.42
Upside: -56.95%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $22.50
Upside: -46.67%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $190.26
Upside: -23.79%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $193.74
Upside: +88.40%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $844.13
Upside: -50.24%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $4.76
Upside: +2,421.01%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $283.95
Upside: +118.35%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $381.93
Upside: +30.91%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $81.36
Upside: +52.41%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $277.94
Upside: +14.41%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $213.46
Upside: -67.21%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $241.28
Upside: -19.18%